n estimated 1 in 4 adults worldwide lives with metabolic dysfunction-associated steatotic liver disease (MASLD), which can progress to metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage of the disease.
Global Liver Institute Applauds FDA Approval of New Chronic Hepatitis B Treatment
Global Liver Institute (GLI) applauds GSK for this advancement in chronic Hepatitis B virus (HBV) treatment following the U.S. Food and Drug Administration (FDA) approval of Hibsago (bepirovirsen).
Global Liver Institute and Commonwealth Medical Association (CMA) sign a Memorandum of Understanding to Advance Liver Health Globally
Global Liver Institute (GLI) and the Commonwealth Medical Association (CMA) have formalised a partnership through a Memorandum of Understanding (MOU), signed on October 1st at the CMA’s Longevity and Healthy Ageing Conference at the Commonwealth Secretariat in London.
A Global Turning Point for Liver Health
Global Fatty Liver Day 2026 comes at a pivotal moment for liver health worldwide.
Together for Steatotic Liver Disease – The Hidden NCDs: SLD as the Next Global Public Health Priority
Yesterday, Global Liver Institute (GLI), in collaboration with the Egyptian Ministry of Health and Population, convened a high-level policy event, on the sidelines of the Seventy-Ninth World Health Assembly (WHA79) to translate this global policy milestone into coordinated action.
Years of Advocacy Have Led to the Adoption of the Resolution “Steatotic Liver Disease: A Missing Piece in Global NCD Response”
Today, at the Seventy-Ninth World Health Assembly Plenary session, member states formally adopted the landmark resolution “Steatotic liver disease: a missing piece in the global noncommunicable disease response”, marking a pivotal moment for the global liver community.
Global Liver Institute Will Convene the Second Edition of Advanced Advocacy Academy (A3) UK
Building on the success of its inaugural year, Global Liver Institute’s A3 UK returns April 10 and 11, 2026. Delivered through a strengthened partnership with King’s College Hospital NHS Foundation Trust and now officially welcoming the British Liver Trust, the program will create a unified platform to advance liver health in the UK while advancing global advocacy, clinical leadership, and national representation.
Croatia Roundtable Elevates Liver Health on Public Health Agendas
Global and national leaders call attention to the growing impact of liver disease Zagreb, Croatia - February 25, 2026 – National health leaders, patient advocates, clinicians, and international experts convened in Zagreb this week for the Croatia Roundtable on Liver...
Global Liver Institute Drives Momentum Behind Landmark WHO Decision on Steatotic Liver Disease and NCDs
Today, at the 158th Executive Board meeting of the World Health Organization (WHO), Member States agreed to include the draft resolution “Steatotic liver disease: a missing piece in the global noncommunicable disease response” on the agenda of the Seventy-Ninth World Health Assembly (WHA79), with a recommendation for adoption in May 2026.
Global Liver Institute’s Fifth #RareAware Campaign Puts Early Detection at the Center of Care
Rare disease patients often have to make 17 medical visits before a diagnosis. Under the theme of Early Detection Drives Direction, Global Liver Institute’s annual #RareAware campaign challenges health systems, policymakers, and communities to recognize rare liver diseases sooner, before missed symptoms determine outcomes.